| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
Nicotinamide phosphoribosyltransferase (NAMPT); NAD⁺ biosynthesis pathway. P7C3-OMe functions by stabilizing nicotinamide phosphoribosyltransferase (NAMPT) activity, thereby boosting NAD⁺ biosynthesis and supporting cellular energy homeostasis. By enhancing NAD⁺ levels, it promotes neuronal survival and neurogenesis. The R-enantiomer is far more active than the S-enantiomer.
|
|---|---|
| ln Vitro |
P7C3-OMe is a pro-neurogenic compound that enhances neuronal survival and promotes neurogenesis. It functions by stabilizing NAMPT activity and boosting NAD⁺ biosynthesis. The R-enantiomer of P7C3-OMe is far more active than the S-enantiomer. It has demonstrated protective effects in models of neurodegeneration, traumatic brain injury, and aging-related cognitive decline.
|
| ln Vivo |
In vivo, P7C3-OMe has demonstrated protective effects in models of neurodegeneration, traumatic brain injury, and aging-related cognitive decline. Its improved potency and pharmacokinetics compared to earlier analogs make it a valuable research tool. It is widely studied for its potential in developing therapies for Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.
|
| Enzyme Assay |
Non-cell-based assays for P7C3-OMe include NAMPT activity assays measuring the enzyme's ability to produce nicotinamide mononucleotide (NMN). NAD⁺ levels can be measured using enzymatic cycling assays or HPLC. The compound's ability to stabilize NAMPT and enhance NAD⁺ biosynthesis is assessed in cell-free systems. Standard analytical methods including HPLC, NMR, and mass spectrometry are used for compound characterization.
|
| Cell Assay |
Cell-based assays for P7C3-OMe use neuronal cell lines to assess neuroprotective and pro-neurogenic activities. Cells are treated with the compound at various concentrations, and neuronal survival, neurite outgrowth, and neurogenesis are assessed. NAD⁺ levels are measured in cell lysates. The compound's protective effects against oxidative stress, excitotoxicity, or other insults are evaluated. Cytotoxicity is assessed using standard cell viability assays.
|
| Animal Protocol |
In vivo studies of P7C3-OMe are conducted in animal models of neurodegeneration, traumatic brain injury, and aging-related cognitive decline. The compound is administered via oral or intraperitoneal injection. Cognitive function, neuronal survival, neurogenesis, and NAD⁺ levels in the brain are assessed. Pharmacokinetic parameters are determined from blood and tissue samples. The compound is studied for its potential in treating Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.
|
| ADME/Pharmacokinetics |
P7C3-OMe has a molecular formula of C₂₂H₂₀Br₂N₂O₂ and a molecular weight of 504.21 g/mol. Purity is ≥95%. The IUPAC name is 1-(3,6-dibromocarbazol-9-yl)-3-(3-methoxyanilino)propan-2-ol. It is a neuroprotective small-molecule derivative of the P7C3 series. It should be stored under recommended conditions.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for P7C3-OMe are limited. As a neuroprotective compound, it is generally considered to have low toxicity at therapeutic doses. The R-enantiomer is far more active than the S-enantiomer. Standard laboratory safety practices should be followed when handling this compound. It is intended for research use only.
|
| References |
[1]. Pieper AA, et al. Discovery of a proneurogenic, neuroprotective chemical. Cell. 2010 Jul 9;142(1):39-51.
|
| Additional Infomation |
P7C3-OMe is a neuroprotective small-molecule derivative of the P7C3 series, known for enhancing neuronal survival and promoting neurogenesis. It functions by stabilizing nicotinamide phosphoribosyltransferase (NAMPT) activity, thereby boosting NAD⁺ biosynthesis and supporting cellular energy homeostasis. The R-enantiomer is far more active than the S-enantiomer. It has demonstrated protective effects in models of neurodegeneration, traumatic brain injury, and aging-related cognitive decline. It is for research use only.
|
| Molecular Formula |
C22H20N2O2BR2
|
|---|---|
| Molecular Weight |
504.214
|
| Exact Mass |
503.987
|
| CAS # |
313268-18-7
|
| Related CAS # |
(S)-P7C3-OMe;1235481-43-2
|
| PubChem CID |
3103961
|
| Appearance |
White to off-white solid powder
|
| LogP |
5.7
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
28
|
| Complexity |
485
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=CC=CC(=C1)NCC(CN2C3=C(C=C(C=C3)Br)C4=C2C=CC(=C4)Br)O
|
| InChi Key |
LEICNUMXFWNCSJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H20Br2N2O2/c1-28-18-4-2-3-16(11-18)25-12-17(27)13-26-21-7-5-14(23)9-19(21)20-10-15(24)6-8-22(20)26/h2-11,17,25,27H,12-13H2,1H3
|
| Chemical Name |
1-(3,6-dibromocarbazol-9-yl)-3-(3-methoxyanilino)propan-2-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ≥ 100 mg/mL (198.33 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.96 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.96 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9833 mL | 9.9165 mL | 19.8330 mL | |
| 5 mM | 0.3967 mL | 1.9833 mL | 3.9666 mL | |
| 10 mM | 0.1983 mL | 0.9917 mL | 1.9833 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
